- UBS started off coverage on Repligen ( NASDAQ: RGEN ) with a Buy rating and $213 price target as part of a broader research note on life sciences & diagnostic tools.
- The analyst is positive on the company being most levered to biologics and large pharma trends, stating that its guidance through 2025 anticipates over 20% top-line trajectory.
- Repligen reported 44.5% growth in first quarter 2022 revenue to $206.4M with profits topping the consensus mark.
- Shares are up 5% , Wednesday.
- The stock is down 36% year-to-date but has gained momentum over the past one-month at +17.7% return .
- Wall Street analysts , on an average, give Strong Buy on RGEN same as SA Authors while Seeking Alpha Quant rating flags a Hold.
For further details see:
Repligen attracts initial bull rating at UBS Group on long-term growth prospects